MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -89.36%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.67 per share when it actually produced a loss of $0.84, delivering a surprise of -25.37%. Over the last four quarters, the com ...